Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Hupperts… - New England Journal …, 2012 - cris.maastrichtuniversity.nl
Abstract BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective
properties in preclinical experiments and to result in significant reductions in disease activity …
properties in preclinical experiments and to result in significant reductions in disease activity …
[PDF][PDF] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or… - N Engl J …, 2012 - ms.biogenpro.no
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[PDF][PDF] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni… - N Engl J Med, 2012 - biogenpro.no
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[PDF][PDF] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or, G Giovannoni… - N Engl J Med, 2012 - academia.edu
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[PDF][PDF] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or… - N Engl J …, 2012 - researchgate.net
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …
[引用][C] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R GOLD, L KAPPOS, KT DAWSON… - The New England …, 2012 - pascal-francis.inist.fr
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
[引用][C] Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
R Gold, L Kappos, DL Arnold, A Bar-Or… - New England Journal …, 2012 - cir.nii.ac.jp
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
[PDF][PDF] " Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
R Gold, L Kappos, DL Arnold, A Bar-Or… - N Engl J …, 2012 - dial.uclouvain.be
In patients with relapsing-remitting multiple sclerosis, both BG-12 regimens, as compared
with placebo, significantly reduced the proportion of patients who had a relapse, the …
with placebo, significantly reduced the proportion of patients who had a relapse, the …
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis
R Gold, L Kappos, DL Arnold… - The New England …, 2012 - pubmed.ncbi.nlm.nih.gov
Background BG-12 (dimethyl fumarate) was shown to have antiinflammatory and
cytoprotective properties in preclinical experiments and to result in significant reductions in …
cytoprotective properties in preclinical experiments and to result in significant reductions in …